DekaBank Deutsche Girozentrale’s Krystal Biotech KRYS Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15,503	Closed	-$2.63M	–	1248
2025 Q4	$2.63M	Hold	15,503	–	–	﹤0.01%	709
2025 Q3	$2.72M	Hold	15,503	–	–	﹤0.01%	692
2025 Q2	$2.15M	Hold	15,503	–	–	﹤0.01%	729
2025 Q1	$2.82M	Hold	15,503	–	–	0.01%	669
2024 Q4	$2.44M	Hold	15,503	–	–	﹤0.01%	708
2024 Q3	$2.72M	Hold	15,503	–	–	0.01%	699
2024 Q2	$2.83M	Hold	15,503	–	–	0.01%	686
2024 Q1	$2.71M	Hold	15,503	–	–	0.01%	696
2023 Q4	$1.97M	Hold	15,503	–	–	﹤0.01%	776
2023 Q3	$1.81M	Sell	15,503 -14,797	-49%	-$1.81M	﹤0.01%	766
2023 Q2	$3.47M	Hold	30,300	–	–	0.01%	633
2023 Q1	$2.35M	Hold	30,300	–	–	0.01%	696
2022 Q4	$2.38M	Hold	30,300	–	–	0.01%	684
2022 Q3	$2.11M	Hold	30,300	–	–	0.01%	698
2022 Q2	$1.92M	Buy	30,300 +5,000	+20%	+$311K	0.01%	738
2022 Q1	$1.69M	Buy	25,300 +16,500	+188%	+$1.03M	﹤0.01%	792
2021 Q4	$619K	Buy	8,800 +200	+2%	+$11.6K	﹤0.01%	1049
2021 Q3	$453K	Hold	8,600	–	–	﹤0.01%	1073
2021 Q2	$586K	Hold	8,600	–	–	﹤0.01%	1039
2021 Q1	$622K	Buy	8,600 +2,200	+34%	+$160K	﹤0.01%	990
2020 Q4	$361K	Buy	+6,400	New	+$320K	﹤0.01%	1089

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DekaBank Deutsche Girozentrale's KRYS Position: Q1 2026 in Review

DekaBank Deutsche Girozentrale sold out of Krystal Biotech (KRYS) in Q1 2026, closing a stake of 15,503 shares — an estimated $2.63M sold.

DekaBank Deutsche Girozentrale first reported a position in KRYS in Q4 2020 and held it in 21 quarters. The position peaked at $3.47M in Q2 2023. 368 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

DekaBank Deutsche Girozentrale reported no remaining Krystal Biotech position as of Q1 2026 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 15,503 Krystal Biotech shares in Q1 2026, an estimated $2.63M.
DekaBank Deutsche Girozentrale first reported a position in Krystal Biotech in Q4 2020 and held it in 21 quarters.
DekaBank Deutsche Girozentrale's Krystal Biotech position peaked at $3.47M in Q2 2023.
368 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2026, filed 7 May 2026.